Bradley Paul Morgan, SVP Drug Discovery & Early Development at CYTOKINETICS INC (CYTK), sold 118,330 shares at $15.00 ($1.8M) on 2017-08-31, disclosed to the SEC on 2017-09-01.
Open-market sale of $1.8M CYTK by SVP Drug Discovery & Early Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.00 | 617 | $9K | 0.5% |
| 2 | $15.00 | 694 | $10K | 0.6% |
| 3 | $15.00 | 695 | $10K | 0.6% |
| 4 | $15.00 | 1,079 | $16K | 0.9% |
| 5 | $15.00 | 2,294 | $34K | 1.9% |
| 6 | $15.00 | 2,638 |
| $40K |
| 2.2% |
| 7 | $15.00 | 2,639 | $40K | 2.2% |
| 8 | $15.00 | 3,795 | $57K | 3.2% |
| 9 | $15.00 | 11,552 | $173K | 9.8% |
| 10 | $15.00 | 11,883 | $178K | 10.0% |
| 11 | $15.00 | 13,448 | $202K | 11.4% |
| 12 | $15.00 | 13,920 | $209K | 11.8% |
| 13 | $15.00 | 15,206 | $228K | 12.9% |
| 14 | $15.00 | 16,666 | $250K | 14.1% |
| 15 | $15.00 | 21,204 | $318K | 17.9% |
| Total | $15.00 avg | 118,330 | $1.8M | 100% |